Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 92 The United Laboratories International Holdings Limited Annual Report 2019 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2018 Intermediate Bulk Finished Unallocated products medicine products expenses Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of prepaid lease payments 4,264 1,047 1,274 – 6,585 Amortisation of intangible assets 1,840 – 10,444 – 12,284 Depreciation of property, plant and equipment 578,753 97,889 48,212 3,901 728,755 Impairment losses recognised on intangible assets – – – 17,960 17,960 Net loss on disposal of property, plant and equipment – – – 29,529 29,529 Impairment losses under expected credit loss model, net of reversal (1,036) (2,846) (2,424) 8,412 2,106 (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2019 2018 RMB’000 RMB’000 PRC (country of domicile) 5,957,571 5,541,842 Europe 642,620 570,821 India 833,723 532,060 Hong Kong 87,943 33,601 Middle East 44,353 48,234 South America 234,337 151,704 Other Asian regions 366,692 421,675 Other regions 225,361 210,649 8,392,600 7,510,586